Requip® XL 24-Hour™

Partner: GlaxoSmithKline

Therapeutic benefit for Parkinson’s disease patients, extending the product patent and allowing for improved positioning for GSK’s Requip®

Requip®  XL 24-Hour™ (ropinirole) for Parkinson’s disease was developed in partnership with GlaxoSmithKline.

A recent study (1) showed that Requip® XL 24-Hour™ in Parkinson’s disease patients on levodopa therapy significantly reduced the “off” time, thus allowing patients to continue their daily activities for a longer period of time.

Filed for approval at the end of 2005, regulatory approvals were received in France in April 2007, followed by approval in a number of European markets.  It has also been approved in Canada. The US new drug application was accepted for filing by the FDA in April 2007 and an approvable letter was received in December 2007.

For further information on Requip® XL 24-Hour™, see GlaxoSmithKline's web site.

Reference:
1. Pahwa, R., Stacy, M. A., Factor, S. A., Lyons, K. E., Stocchi, F., Hersh, B. P., Elmer, L. W., Truong, D. D., Earl, N. L., on behalf of the EASE-PD Adjunct Study Investigators, Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease, Neurology 2007 68: 1108-1115

Copyright 2008, SkyePharma. All Rights Reserved.

SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom

gsk